These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26362006)

  • 1. Measuring Transcription Rate Changes via Time-Course 4-Thiouridine Pulse-Labelling Improves Transcriptional Target Identification.
    Schwarzl T; Higgins DG; Kolch W; Duffy DJ
    J Mol Biol; 2015 Oct; 427(21):3368-74. PubMed ID: 26362006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma.
    Duffy DJ; Krstic A; Halasz M; Schwarzl T; Fey D; Iljin K; Mehta JP; Killick K; Whilde J; Turriziani B; Haapa-Paananen S; Fey V; Fischer M; Westermann F; Henrich KO; Bannert S; Higgins DG; Kolch W
    Oncotarget; 2015 Dec; 6(41):43182-201. PubMed ID: 26673823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYCN oncoprotein targets and their therapeutic potential.
    Bell E; Chen L; Liu T; Marshall GM; Lunec J; Tweddle DA
    Cancer Lett; 2010 Jul; 293(2):144-57. PubMed ID: 20153925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
    Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
    Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
    Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
    Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Labeling of Newly Synthesized RNA with 4sU to in Parallel Assess RNA Transcription and Decay.
    Sun W; Chen W
    Methods Mol Biol; 2018; 1720():25-34. PubMed ID: 29236249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correcting 4sU induced quantification bias in nucleotide conversion RNA-seq data.
    Berg K; Lodha M; Delazer I; Bartosik K; Garcia YC; Hennig T; Wolf E; Dölken L; Lusser A; Prusty BK; Erhard F
    Nucleic Acids Res; 2024 Apr; 52(7):e35. PubMed ID: 38381903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiouridine-to-Cytidine Conversion Sequencing (TUC-Seq) to Measure mRNA Transcription and Degradation Rates.
    Lusser A; Gasser C; Trixl L; Piatti P; Delazer I; Rieder D; Bhasin JM; Riml C; Amort T; Micura R
    Methods Mol Biol; 2020; 2062():191-211. PubMed ID: 31768978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergising single-cell resolution and 4sU labelling boosts inference of transcriptional bursting.
    Edwards DM; Davies P; Hebenstreit D
    Genome Biol; 2023 Jun; 24(1):138. PubMed ID: 37328900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
    Gupta A; Williams BR; Hanash SM; Rawwas J
    Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
    Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
    Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma.
    Alaminos M; Mora J; Cheung NK; Smith A; Qin J; Chen L; Gerald WL
    Cancer Res; 2003 Aug; 63(15):4538-46. PubMed ID: 12907629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition-Elimination Mechanism-Activated Nucleotide Transition Sequencing for RNA Dynamics Profiling.
    Su L; Chen F; Yu H; Yan H; Zhao F; Fan C; Zhao Y
    Anal Chem; 2021 Oct; 93(41):13974-13980. PubMed ID: 34612623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
    Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
    Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
    Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
    Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
    Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.
    Liu PY; Erriquez D; Marshall GM; Tee AE; Polly P; Wong M; Liu B; Bell JL; Zhang XD; Milazzo G; Cheung BB; Fox A; Swarbrick A; Hüttelmaier S; Kavallaris M; Perini G; Mattick JS; Dinger ME; Liu T
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.